Eli Lilly cut its outlook for fourth-quarter revenue citing sluggish growth in the market for incretin, which increases insulin levels.
Trending
- Berlin, Paris urge restraint as Israel-Iran crisis escalates – DW – 06/14/2025
- Vivatech 2025: Is Europe lagging behind?
- Unlocking the Power of Crypto Trading Leverage Tool
- Casino Electric Wins Unleash Your Luck and Electrify Your Gameplay
- Luxury brands are more expensive than ever. They’re telling you why they’re worth it
- The large sports legging trend of 2025? That’s this one
- wanneer debuten schommelen tussen hype en onbeduidendheid
- Rosario Dawson’s ‘Kiss My Grass’ Doc Spotlights Black Women In Cannabis
